The **Membranous Nephropathy Market** is currently in a phase of dynamic transformation, primarily fueled by substantial R&D investment directed towards novel therapeutic targets. Following the success of B-cell depletion with rituximab, the pharmaceutical pipeline is expanding to explore alternative mechanisms of action, particularly those targeting the complement pathway, T-cell...